MedTrace Logo

Intravenous Continuous LMWH Seems to Be Safe Alternative to UFH in VV ECMO Patients

NCT06010446 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2025-02-25

No results posted yet for this study

Summary

Unfractionated heparin (UFH) is worldwide anticoagulation used and recommended anticoagulation in patients with ECMO support. However, it is accompanied with incidence of bleeding or thrombotic compliaction at about 40-60% and high mortality. Because ECMO produce primary haemosthasis pathology, there is a theory that prophylaxis of thrombosis with low molecular weight heparin (LMWH) e.g. Enoxaparin might be sufficient to prevent ECMO throbosis and thrombosis development in patients.

We decided to performed retrospective observation study and analysis of data, from may 2019 until august 2023, in all patients who were put on VV ECMO and to analysis incidence of bleeding, thrombotic and neurologic complications.

Conditions

  • Refractory Respiratory Failure

Interventions

OTHER

No intervention, just retrospective analysis of data.

Sponsors & Collaborators

  • University Hospital, Motol

    lead OTHER

Principal Investigators

  • Miroslav Durila, prof. · Department of anesthesiology and intensive care medicine, Motol Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-15
Primary Completion
2023-08-15
Completion
2023-08-15

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06010446 on ClinicalTrials.gov